william e aliski executive profile  biography  bloomberg july    pm et biotechnology company overview of ultragenyx pharmaceutical inc snapshotpeople  overviewboard memberscommittees executive profile william e aliski director ultragenyx pharmaceutical incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr william e aliski also known as bill served as the chief commercial officer and senior vice president of foldrx pharmaceuticals inc mr aliski has wealth of experience advancing novel therapies for the treatment of orphan diseases to market he has over  years experience in the biotechnology industry with the majority of that time focused on the orphan drug market prior to foldrx pharmaceuticals he served as senior director of simon kucher partners a global  consulting company specializing in pricing and reimbursement mr aliski served as vice president of biomarin pharmaceutical inc since january  and as its general manager of european operations from january  to january  mr aliski served as vice president and general manager of european operations at biomarin europe ltd where he helped to establish and initiated commercial operations to launch naglazyme an enzyme replacement therapy for the treatment of mps vi maroteaux lamy syndrome a rare genetic disease from august  to october  mr aliski served as vice president of commercial operations at shire human genetic therapies hgt formerly transkaryotic therapies a biotechnology company that prior to its acquisition by shire pharmaceuticals group in july  focused on the development and commercialization of products to treat rare diseases at transkaryotic mr aliski managed worldwide drug distribution inventory management and patient support for transkaryotics lead product replagal an enzyme replacement therapy for fabry disease from september  to august  mr aliski worked at genzyme corporation a biopharmaceutical company focused on serious diseases including genetic disorders where he served as vice president of health systems and vice president of patient and product services responsible for oversaw the development and implementation of reimbursement planning and launch for multiple products including cerezyme and ceredase he has been an independent director of edimer pharmaceuticals inc since may   he has been director of scioderm llc since december  he has been a director of ultragenyx pharmaceutical inc since january  mr aliski received a master in public administration from the kennedy school of government at harvard university and a bs degree in economics and a masters of social planning from boston collegeread full background corporate headquarters  leveroni courtnovato california united statesphone fax  board members memberships presentdirectorultragenyx pharmaceutical incpresentindependent directoredimer pharmaceuticals incpresentdirectorscioderm llc education masters degree harvard universitybs boston collegemasters degree boston college other affiliations biomarin pharmaceutical incharvard universityboston collegefoldrx pharmaceuticals incbiomarin europe ltdedimer pharmaceuticals incscioderm llc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation total annual cash compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact ultragenyx pharmaceutical inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close william aliski general manager european operations bio marin pharmaceutical inc  spoke login register add company add person add topic login or home  people  william aliski advanced search faq javascript is disabled bio edit william aliski bill aliski general manager european operations bio marin pharmaceutical inc novato ca find other people named william aliski general info research and development in the physical engineering and life sciences add tags— eg finance businessbusiness william e aliski vice president and general manager european operations mr aliski joined biomarin in december  as vice president and general manager european operations prior to joining biomarin mr aliski held the position of vice president commercial operations at transkaryotic therapies tkt acquired by shire pharmaceuticals group in july  where he managed worldwide drug distribution inventory management and patient support for the company’s lead product replagal an enzyme replacement therapy for fabry disease additionally while at tkt mr aliski was responsible for market development and sales for non european countries and pricing and reimbursement for company products worldwide including preparation of reimbursement filings and price negotiations with foreign governments and all commercial distribution agreements earlier in his career mr aliski worked at genzyme corporation where he served as vice president health systems and vice president patient and product services responsible for overseeing the development and implementation of reimbursement planning and launch for multiple products including cerezyme and ceredase mr aliski received a masters of public administration from the kennedy school of government at harvard university and a bachelors of science degree in economics and a masters of social planning from boston college not who youre looking for find other william aliskis on spoke contact telephone email background report public records powered by digital info wwwbiomarinpharmcom na na na na na na resume edit career bio marin pharmaceutical inc general manager european operations education edit add a degree— eg bachelors in business administration blogs by industry voices there are currently no blogs by industry voices achievements and recognition edit add an achievement andor recognition— eg man of the year forbes  notable links edit the links below are powered by bing search results click edit to customize videos edit add a videofrom youtube or vimeo executives  featured people at bio marin pharmaceutical inc gwynn williams trustee apr kim mcroberts documentation supervisor feb james dickow jdickowbmrncom jeff ajer vice president of sales and marketing operations r ramelmeier vice president manufacturing and process development mark wood vice president human resources charles oneill vice president pharmacological sciences stephen aselage senior vice president global commercial development daniel maher vice president product development robert baffi senior vice president technical operations created on jun   by spoke   edited on jun   by spoke   page completion  career summary industry websiteblog add education add a social network add a video add  notable links add  achievements add a photo view more view less share this page add page add company add person add topic copy this code to embed a widget div idspokerootdiv scriptfunctiond s id document script spokewidgetjsscript div classspokewidget datahostwwwspokecom datatypeperson dataidecece datawidth dataheight datascrollno dataframebordernonediv div stylefontsize pta hrefhttpwwwspokecompeoplewilliamaliskiececewilliam aliskia widget provided by a hrefhttpwwwspokecomspokeadiv public records our partner can help you find public records for william more on some of spokes content providers become a spoke content provider learn more   bill aliski  board of directors  ultragenyx board of directors william aliski biotechnology executive director william aliski has served as a member of the ultragenyx board since january  mr aliski previously served as a commercial consultant for earlystage orphan disease companies including enobia pharma from september  until march  before that mr aliski served as senior vice president and chief commercial officer of foldrx pharmaceuticals a rare disease company that is now a whollyowned subsidiary of pfizer inc from june  until march  as director of simon kucher partners a global consulting firm from january  until june  and as general manager of biomarin europe at biomarin pharmaceuticals inc from december  until january  mr aliski received a bs in economics and a master of social planning from boston college and an mpa from the kennedy school of government at harvard university he has extensive leadership and management experience in the life sciences industry and is a member of various boards of directors about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions privacy policy   ultragenyx pharmaceuticalwebsite design hane chow inc privacy policy william aliski  unitedhealth group inc  zoominfocom william aliski   boston business journal menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now energy solutions for business we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases subscribers subscriberonly content digital edition start a subscription sign up for newsletters lists  awards lists all lists access the book of lists purchase the book of lists build your own lists submit your company to be on a list awards nominate for an award people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations add your event event photos signature events bizwomen mentoring monday more… jobs find or post a job in boston store subscriptions reprints  more sales leads public records information to build your business how to grow your business advance your career home of the day premium real estate listings in boston bizspace best office spaces available in boston thought leadership trends tips and insights from our partners bioflash newsletter real estate inc newsletter startups newsletter techflash newsletter five things to know startups  venture capital subscribers start a subscription subscriberonly content digital edition access the book of lists purchase the book of lists manage your account about  contact about us about the business journals advertise help  faqs contact us call center directory apps  syndication newsletters mobile apps syndicationrss acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  sponsored by people on the move email facebook linkedin twitter print  of  ltimg srchttpsassetsbizjournalscomlibimgnewsleemptyiconpng altwilliam aliskigt board of directors health care may   william aliski independent director at edimer pharmaceuticals william aliski has  years of experience in the biotechnology industry with the majority of that time focused on the orphan drug market in the us he established the first comprehensive patient assistance program for genzyme to support their flagship product ceredasecerezyme as general manger for biomarin europe he established the company in the european union and launched naglazyme for maroteauxlamy syndrome mps vi more recently he was the chief commercial officer for foldrx which was acquired by pfizer in  and established pre approval sales initiative for vyndaqel in europe he now serves on the board of directors of ultragenyx a developmentstage company focused on ultra orphan diseases  download contact information download sample vcard file more people on the move ltimg srchttpsassetsbizjournalscombostonusermediaalexandraabramowitzjpeg altalexandra abramowitzgt media  marketing alexandra abramowitz schneider associates ltimg srchttpsassetsbizjournalscombostonusermediadavisbradfordjpeg altdavis bradfordgt other davis bradford slalom consulting ltimg srchttpsassetsbizjournalscombostonusermediajanmoidelschwartzjpeg altjan moidel schwartzgt other jan moidel schwartz synagogue council of massachusetts ltimg srchttpsassetsbizjournalscombostonusermediarobertkalerjpeg altrobert kalergt legal services robert kaler holland  knight llp see more people on the move promote employees and keep your companys name in the news for  submit people on the move sign up for newsletters  alerts receive boston business journals morning edition and afternoon edition newsletters and breaking news alerts sign up next person on the move img srchttpsmediabizjusviewimgemilyreithxxjpg altemily reith residential real estate emily reith lendlease special offer subscribe now to search our database of  boston business journal people on the move submissions and download their contact information subscribe to download contacts people around the country img srchttpsmediabizjusviewimgstephenshutexxpng altstephen shute stephen shute sap img srchttpsmediabizjusviewimgbryanvielhauerxxjpg altbryan vielhauer bryan vielhauer decal impressions img srchttpsmediabizjusviewimgmattewwrightxxjpg altmatthew wright matthew wright st community mortgage co see all people on the move featured jobs denver co vice president of economic development downtown denver partnership inc philadelphia pa president archbishop ryan high school archdiocese of philadelphia pittsburgh pa commercial real estate agent aegis realty partners buffalo ny intellectual property attorney bond schoeneck  king pllc albany ny cash management officer pioneer bank post a job see all jobs edimer appoints william aliski and wendy l dixon phd to board of directors  business wire edimer appoints william aliski and wendy l dixon phd to board of directors company broadens expertise in commercialization and reimbursement as preparations begin for phase  trial of their lead compound edi may    am eastern daylight time cambridge massbusiness wireedimer pharmaceuticals a biotechnology company focused on developing an innovative therapy for the rare genetic disorder xlinked hypohidrotic ectodermal dysplasia xlhed today announced the appointment of william aliski and wendy l dixon phd to the company’s board of directors mr aliski a global biotech executive and orphan disease expert and dr dixon an industry veteran who has launched more than  pharmaceutical products will serve as independent directors for edimer with these additions edimer extends gratitude and appreciation for the counsel provided by dan lynch who will now step down from his position on the board “we are at an important inflection point for our company we have recently completed dosing in our phase  clinical trial of edi and we will soon be recruiting subjects for the phase  neonate trial” said neil kirby phd president and ceo of edimer “we enthusiastically welcome bill and wendy to the board i am confident that their broad expertise and experience will be of tremendous value as we enter the next phase of edimer’s development” “edimer is pioneering a whole new approach for the treatment of a genetic disease” said mr aliski “i look forward to sharing my experience in the orphan disease market to help achieve success for edimer and especially for future generations affected by xlhed” “it is exciting to be part of a company that is leveraging such an innovative approach to address such a severe and potentially lifethreatening disease” said dr dixon “i look forward to working closely with the edimer team to deliver on this unprecedented endeavor” mr aliski has twenty five years experience in the biotechnology industry with the majority of that time focused on the orphan drug market bill has held leadership positions in a variety of settings from startup to well established global companies with responsibility for bringing orphan drugs to market and addressing the challenges of market access around the world in the us he established the first comprehensive patient assistance program for genzyme to support their flagship product ceredasecerezyme as general manger for biomarin europe he established the company in the european union and launched naglazyme for maroteauxlamy syndrome mps vi more recently he was the chief commercial officer for foldrx which was acquired by pfizer in  and established pre approval sales initiative for vyndaqel in europe bill now serves on the board of directors of ultragenyx a development stage company focused on ultra orphan diseases he received a bs in economics from boston college and a master in public administration from harvard university dr dixon was formerly the chief marketing officer and president of global marketing for bristolmyers squibb her year career in the pharmaceutical and biotechnology industries has included senior roles in drug development regulatory affairs and commercialization during her career dr dixon has launched and driven the growth of more than  pharmaceutical products including tagamet fosamax singulair plavix abilify reyataz and baraclude previously she held a series of leadership positions at merck west pharmaceuticals osteotech and centocor dr dixon serves on the boards of directors of alkermes plc incyte corporation orexigen therapeutics furiex pharmaceuticals and formerly on ardea biosciences inc sold to astrazeneca plc in  and dentsply international she received her msc and bsc in natural science and her phd in biochemistry from university of cambridge about edi edi is an ectodysplasina edaa replacement protein representing the first of a new class of molecules rationally designed to correct a specific developmental disorder edi has been shown to bind specifically to the edaa receptor activating the signaling pathways that lead to normal development edi has demonstrated substantial and durable efficacy in animal models of xlhed with notable reduction in mortality and morbidity the us food and drug administration fda granted orphan drug designation and fast track status to edi edi also has orphan drug designation in europe about xlhed xlhed also known as christsiemenstouraine syndrome is a rare disorder of development resulting from genetic mutations in the ectodysplasin gene eda patients affected by xlhed are at risk for lifethreatening hyperthermia based on their inability to regulate body temperature and for clinicallysignificant pneumonias resulting from their abnormality in respiratory secretions cardinal signs and symptoms in xlhed include diminishedabsent sweat reduced and abnormal airway secretions few and often misshapen teeth and absent or early hair loss from face and scalp xlhed patients surviving infancy are predisposed to atopy presenting with eczema and asthma chronic sinusitis recurrent nose bleeds and dry eye complications almost uniformly they require dental interventions including early prostheses and later implants their susceptibility to hyperthermia facial appearance abnormal dentition and hair loss may impact normal participation in outdoor activities sports and school attendance both medical and selfesteem issues are lifelong in this disorder as is generally true with xlinked inheritance males are fully affected while females are variably affected about edimer pharmaceuticals edimer is a privately held biotechnology company based in cambridge massachusetts dedicated to delivering a significant and durable improvement in the health and quality of life for future generations affected by xlhed edimer was established in  with investment from third rock ventures and vi partners for further information on edimer pharmaceuticals please visit wwwedimerpharmacom to receive regular updates about edimer pharmaceuticals’ progress please join the xlhed network at wwwxlhednetworkcom contacts edimer pharmaceuticalsneil kirby phd president  ceo orsuda communications llcmaureen l suda media  release summary edimer pharmaceuticals adds two new board members with reimbursement and commercialization expertise as company prepares for phase  trial of edi for treatment of rare genetic disease xlhed contacts edimer pharmaceuticalsneil kirby phd president  ceo orsuda communications llcmaureen l suda media  search advanced news search advanced news search log in sign up william aliski at biomarin pharmaceutical inc contact details  leadferretcom login with your social account or  forgot password create a free accountsign up leadferret search contacts specialty directories about us blog company faqs partners careers contact us privacy policy help faq tutorials buy points earn points salesnexus  company  contact directories companies contacts contact details for william aliski william aliski manager contact information phone   email please log in or register to see the details social links twitter please log in or register to see the details facebook please log in or register to see the details linkedin please log in or register to see the details google please log in or register to see the details company information name biomarin pharmaceutical inc address  digital dr novato ca  phone  website httpwwwbmrncom view complete company profile claim profile is this you claim your profile to update andor remove this information quality scoreout of  please note this contacts quality score is below our quality threshold this data could be outdated and is not guaranteed to be accurate list of colleagues of william aliski at biomarin pharmaceutical inc first name last name title lewis chapman vice presidentglobal marketing tabitha santoso regulatory affairs associate jill laufer graphic designer hank szeto senior director of engineering and facilties paul kostel proc engineer ii olga smith senior sales data analyst mike gaal pc technician or desktop support or helpdesk or webmaster jeffrey cooper vice presidentacting chief financial officer stephen wilburn network administrator paul mullen engineer david wertzberger director of sales elizabeth nelson cra ii katie workman senior clinical research associate luanne osborn payroll analyst jeff wells manager compliance karen wesley regulatory affairs associate ii stephanie kim director regulatory affairs amy kenner quality assurance senior manager gia depillis director kimberly saame regulatory associate ii lisa bell technology director richard lanyi manager computer system validation sharon stothard clinical training  sop manager debra rose director gcp compliance heather sanders clinical project manager adele french supervisor accounts payable mercedes shinoharataylor project manager linda scott senior director clinical operations matt patterson ragovernment affairs vice president andrew ramelmeier vice president manufacturing susan ferris manager of corporate communications daniel maher vice president program management ruhi ahmed electrical engineer research scientist neil miyamoto attorney maria saenz document mngmt coordinator amudu davis clinical supply chain associate brandusa enachescu quality assurance change control assoc jaie hightower administrative assistant john kolada corporate secretary linda harmon regulatory affairs associate i mark butterfield senior supervisor scott harelik regulatory affairs associate  judy walters attorney guru thuduppathy scientist ii thomas morgan director program management office curtis stone manufacturing supervisor steve keve senior scientistpermanant position joe capone manufacturing supervisor thomas oliver manufacturing senior supervisor eric laye information technology support elizabeth morris lead tech ben ben associate director regulatory affairs elaine heron chairman victoria sluzky vice president qualityanalytical chem sandra shpilberg senior director of global marketing mark woodis vice president of human resources brian chipman quality assurance manager david shiao information technology operations mark henderson associate director quality assurance marisa hewitt process engineermanufacturing sciences michael muna regulatory affairs associate director brian brandley vice president cora versaggi senior benefits representative deborah perez regulatory affairs associate clare army clinical research associate cra jayanth sridhar associate director cell culture manufac jared macdonald attorney william aliski manager alex kamages business analyst alan lewis director emil kakkis cto jeanjacques bienaime ceo jennifer curtis cto joshua grass cto john jost cto joseph klein director michael grey director martha nicholson executive director pierre lapalme chairman richard meier director stuart swiedler cto craig benson senior manager information technology operations neil james senior director marketing karen kistler vice president packaging operations alphonsus cheng senior manager angela williams director  market access fathima mubarack senior analyst digital media melissa anrig director of quality sean turbeville senior manager medical information david draper associate director finance systems emelinda cornejo quality assurance manager sandra parriott assoc director ben dewees associate director regulatory affairs mary odonovan senior director government affairs stacy drakousis senior regulatory affairs associate lisa barnes purchasing jill jepson brand manager marjorie hefner manager regulatory operations bruno gagnon vice president clinical operations bob purcell director corporate communications javier femenia process engineer  design and development randy montellato assoc director information technology department jeff ajer vice president of sales and marketing operations tory quine human resources manager jean bienaime operation manager marc anthony laboratory information systems administrator aleisha dobbins training manager danny lem network specialist daniel oppenheimer program management program leader pku products kimberly mooney senior clinical research associate pavan jhutti regulatory affairs associate ii robert salido specialist facilities maintenance katie dalessandro executive assistant to president and chief executive officer nathan tsuchiya manufacturing engineer crystal brunelle senior manager purchasing alan jeung manager sales operations jim espinosa facilities tech jose macedo manufacturing technician karelle slater regulatory affairs associate brian chipman associate director quality assurance cara wong lab assistant lisa rappl facilities engineer tammy hill regulatory operations senior associate nick grundy manager of information technology enterprise architecture ynez dugan project manager amy waterhouse vice president  regulatory and government affairs jason sullivan senior process engineer kurt yanagimachi process engineer sean mccannell recruiter thomas lester program manager jill wait senior study monitor mona lancaster senior buyerplanner kathryn davidson project manager philip loscalzo deputy general counsel art blum senior director amy kenner manufacturing manager robert baffix senior vice president technical operations victoria sluzky vice president quality palmer lam manager manufacturing joel giacometti senior buyer denise valentino manager global supply chain logistics laurie tsuruda director pharmacology and toxicology deborah holland associate director global commercial financial planning  analysis brian wheale training application specialist ii michelle charpentier director robert newell associate director gxp compliance robert weedon purification supervisor manufacturing bill coakley director supply chain planning erin stone internal audit manager barbara wuebbels associate director patient advocacy and investigator relations colleen crouch sr manager packaging operations mike peterson human resources associate gouri yogalingam senior scientist daniel david packaging operations coordinator eric davis vice president corporate counsel kimberly carneal manager regulatory affairs advertising and promotion karen kelley clinical project manager jonathan blackie associate director manufacturing michael vigarino business systems senior manager scott jordan senior manager contract manufacturing mary gamble sales operations associate terry milby senior director tracy kretz quality assurance coordinator × – a message from leadferret close new message ↑ leadferret chat loading